Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 31-40 of 55 (Search time: 0.004 seconds).
previous
1
2
3
4
5
6
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Hughes, T.
;
Hochhaus, A.
;
Branford, S.
;
Muller, M.
;
Kaeda, J.
;
Foroni, L.
;
Druker, B.
;
Guilhot, F.
;
Larson, R.
;
O'Brien, S.
;
Rudoltz, M.
;
Mone, M.
;
Wehrle, E.
;
Modur, V.
;
Goldman, J.
;
Radich, J.
2010
Dysregulation of bone remodeling by imatinib mesylate
Vandyke, K.
;
Fitter, S.
;
Dewar, A.
;
Hughes, T.
;
Zannettino, A.
2009
Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Branford, S.
;
Soverini, S.
;
Kim, J.
;
Muller, M.
;
Martinelli, G.
;
Cortes, J.
;
Beppu, L.
;
Gottardi, E.
;
Dongho, K.
;
Erben, P.
;
Shou, Y.
;
Haque, A.
;
Gallagher, N.
;
Radich, J.
;
Hochhaus, A.
2010
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells
Engler, J.
;
Frede, A.
;
Saunders, V.
;
Zannettino, A.
;
White, D.
;
Hughes, T.
2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford, S.
;
Vaz de Melo, J.
;
Hughes, T.
2005
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A.
;
Cambareri, A.
;
Zannettino, A.
;
Boog, B.
;
Doherty, K.
;
Hughes, T.
;
Lyons, A.
2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Branford, S.
;
Yeung, D.
;
Prime, J.
;
Choi, S.
;
Bang, J.
;
Park, J.
;
Kim, D.
;
Ross, D.
;
Hughes, T.
2006
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Zannettino, A.
;
Cambareri, A.
;
Quinn, S.
;
Manley, P.
;
Hughes, T.
2011
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Cortes, J.
;
Hochhaus, A.
;
Hughes, T.
;
Kantarjian, H.
2009
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Baccarani, M.
;
Cortes, J.
;
Pane, F.
;
Niederwieser, D.
;
Saglio, G.
;
Apperley, J.
;
Cervantes, F.
;
Deininger, M.
;
Gratwohl, A.
;
Guilhot, F.
;
Hochhaus, A.
;
Horowitz, M.
;
Hughes, T.
;
Kantarjian, H.
;
Larson, R.
;
Radich, J.
;
Simonsson, B.
;
Silver, R.
;
Goldman, J.
;
Hehlmann, R.
Discover
Author
20
Branford, S.
19
Hochhaus, A.
15
White, D.
13
Kantarjian, H.
12
Larson, R.
12
Saglio, G.
10
Radich, J.
9
Cortes, J.
9
Kim, D.
8
Guilhot, F.
.
next >
Subject
55
Pyrimidines
54
Benzamides
51
Humans
50
Imatinib Mesylate
38
Leukemia, Myelogenous, Chronic, B...
35
Antineoplastic Agents
26
Fusion Proteins, bcr-abl
25
Protein Kinase Inhibitors
21
Male
20
Female
.
next >
Date issued
31
2010 - 2014
24
2002 - 2009